Feedback / Questions
pro-doxorubicin (AVA6000) - Avacta
https://www.businesswire.com/news/home/20230406005353/en/Avacta-Opens-First-Two-US-Clinical-Investigator-Sites-for-AVA6000-Phase-1-Clinical-Study
Apr 6, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next